Rational Advisors LLC Buys New Stake in Gilead Sciences, Inc. (GILD)
Rational Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,100 shares of the biopharmaceutical company’s stock, valued at approximately $170,000.
A number of other institutional investors have also recently modified their holdings of the stock. Stephens Inc. AR boosted its stake in Gilead Sciences by 1.5% during the 3rd quarter. Stephens Inc. AR now owns 69,768 shares of the biopharmaceutical company’s stock valued at $5,653,000 after purchasing an additional 999 shares during the last quarter. Roberts Glore & Co. Inc. IL boosted its stake in Gilead Sciences by 3.5% during the 3rd quarter. Roberts Glore & Co. Inc. IL now owns 26,750 shares of the biopharmaceutical company’s stock valued at $2,167,000 after purchasing an additional 895 shares during the last quarter. Hikari Power Ltd boosted its stake in Gilead Sciences by 9.7% during the 3rd quarter. Hikari Power Ltd now owns 141,930 shares of the biopharmaceutical company’s stock valued at $11,499,000 after purchasing an additional 12,600 shares during the last quarter. Columbia Partners L L C Investment Management acquired a new position in Gilead Sciences during the 3rd quarter valued at about $241,000. Finally, Macquarie Group Ltd. boosted its stake in Gilead Sciences by 26.6% during the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after purchasing an additional 100,741 shares during the last quarter. 75.95% of the stock is owned by institutional investors and hedge funds.
In related news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the transaction, the insider now owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 591,666 shares of company stock worth $44,466,567. 1.30% of the stock is owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the previous year, the business earned $2.75 EPS. The company’s revenue was down 13.2% compared to the same quarter last year. research analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.57%. Gilead Sciences’s payout ratio is 23.66%.
GILD has been the subject of a number of analyst reports. Berenberg Bank set a $96.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Credit Suisse Group reiterated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Finally, Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a research note on Friday, October 13th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $85.53.
COPYRIGHT VIOLATION NOTICE: “Rational Advisors LLC Buys New Stake in Gilead Sciences, Inc. (GILD)” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/01/20/rational-advisors-llc-buys-new-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.